|Bid||225.05 x 1200|
|Ask||243.45 x 1000|
|Day's range||228.34 - 236.80|
|52-week range||117.58 - 236.80|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||N/A|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||228.45|
Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way. Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm. Alnylam has a small handful of medicines on the market, led by its drugs Onpattro and Amvuttra, which are intended to treat peripheral neuropathy caused by hereditary transthyretin amyloidosis (ATTR), which is a rare but deadly and progressively worsening heart disease.
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) are poised to post a new all-time high upon market open Wednesday. The RNA interference (RNAi) drug specialist's stock price rose by as much as 53% in premarket action this morning. Ahead of the opening bell, Alnylam announced that its closely watched phase 3 Apollo-B study of the RNAi therapy, patisiran, in patients with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy met its primary endpoint of change in baseline in the 6-minute walk test at 12 months compared to placebo.
CAMBRIDGE, Mass., August 03, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint o